Bibliometric and visual analysis of occupational exposure related to antineoplastic drugs based on CiteSpace

Abstract

Abstract: Objective To analyze the hotspots and development trends of studies on occupational exposure to antineoplastic drugs in the Web of Science（WOS） core collection database over the past 20 years to provide a reference for subsequent in-depth investigations in this field. Methods Articles on occupational exposure to antineoplastic drugs from January 1,2004 to April 14,2024 were retrieved from the Web of Science core collection database. Cite Space software was used to conduct analysis of publication volume,reference explosion,and keyword frequency in this field. Results After screening,325 articles were obtained,and the overall annual publication volume of articles related to occupational exposure to anti-tumor drugs showed a fluctuating upward trend. The top three keywords in terms of frequency were "occupational exposure"（241）,antineoplastic drugs"（134）,and "cyclophosphamide"（101）.Through keyword cluster analysis,10 clusters were identified,covering topics such as cleanliness,lymphocytes,environmental pollution,and occupational disease hazards. The top five countries with the highest number of publications were Italy,the United States,France,Canada,and Japan. Conclusion The overall number of publications on occupational exposure related to antineoplastic drugs shows a slow growth trend,with a large number of publications on environmental residue monitoring,process monitoring,and health risk assessment of antineoplastic drugs,and the publishing countries are mostly developed countries. Currently,the incidence rate of cancer is rising year by year,and the number and duration of medical staff handling antineoplastic drugs are also increasing,so the management awareness of occupational safety of antineoplastic drugs should be improved for the medical staff.

Key words: Antineoplastic drug, Occupational exposure, Bibliometric analysis, Visualization analysis

CLC Number:

R181.2

LIANG Hengjuan, YANG Bo, HUANG Xiaohong. Bibliometric and visual analysis of occupational exposure related to antineoplastic drugs based on CiteSpace. [J]OCCUPATION AND HEALTH, 2025, 41(14): 1985-1992.

References

[1] VANNESTE D,VERSCHEURE E,SRINIVASAN A N,et al.Systematic review of genotoxicity induced by occupational exposure to antineoplastic drugs[J].Arch Toxicol,2023,97(6):1453-1517.
[2] LESO V,SOTTANI C,SANTOCONO C,et al.Exposure to antineoplastic drugs in occupational settings:A systematic review of biological monitoring data[J].Int J Environ Res Public Health,2022,19(6):3737.
[3] CONNOR T H,LAWSON C C,POLOVICH M,et al.Reproductive health risks associated with occupational exposures to antineoplastic drugs in health care settings:A review of the evidence[J].J Occup Environ Med,2014,56(9):901-910.
[4] VILLARINI M,GIANFREDI V,LEVORATO S,et al.Occupational exposure to cytostatic/antineoplastic drugs and cytogenetic damage measured using the lymphocyte cytokinesis-block micronucleus assay:A systematic review of the literature and meta-analysis[J].Mutat Res Rev Mutat Res,2016,770(Pt A):35-45.
[5] HUANG H,GU Y,LIU S,et al.The meta-analysis of cytogenetic biomarkers as an assessment of occupational risk for healthcare workers exposed to antineoplastic drugs[J].Int Arch Occup Environ Health,2023,96(6):785-796.
[6] FRANSMAN W,VERMEULEN R,KROMHOUT H.Dermal exposure to cyclophosphamide in hospitals during preparation,nursing and cleaning activities[J].Int Arch Occup Environ Health,2005,78(5):403-412.
[7] KROMHOUT H,HOEK F,UITTERHOEVE R,et al.Postulating a dermal pathway for exposure to anti-neoplastic drugs among hospital workers.Applying a conceptual model to the results of three workplace surveys[J].Ann Occup Hyg,2000,44(7):551-560.
[8] SESSINK P J,CERNÁ M,RÖSSNER P,et al.Urinary cyclophosphamide excretion and chromosomal aberrations in peripheral blood lymphocytes after occupational exposure to antineoplastic agents[J].Mutat Res,1994,309(2):193-199.
[9] FRANSMAN W,ROELEVELD N,PEELEN S,et al.Nurses with dermal exposure to antineoplastic drugs:Reproductive outcomes[J].Epidemiology,2007,18(1):112-119.
[10] KOPP B,SCHIERL R,NOWAK D.Evaluation of working practices and surface contamination with antineoplastic drugs in outpatient oncology health care settings[J].Int Arch Occup Environ Health,2013, 86(1):47-55.
[11] HON C Y,TESCHKE K,SHEN H,et al.Antineoplastic drug contamination in the urine of Canadian healthcare workers[J].Int Arch Occup Environ Health,2015,88(7):933-941.
[12] 生态环境部.重点管控新污染物清单(2023年版)[J].中华人民共和国国务院公报,2023(5):19-24.
[13] LI B,HU K,LYSENKO V,et al.A scientometric analysis of agricultural pollution by using bibliometric software VoSViewer and Histcite^TM[J].Environ Sci Pollut Res Int,2022,29(25):37882-37893.
[14] PETHRAN A,SCHIERL R,HAUFF K,et al.Uptake of antineoplastic agents in pharmacy and hospital personnel.Part I:monitoring of urinary concentrations[J].Int Arch Occup Environ Health,2003,76(1):5-10.
[15] TURCI R,SOTTANI C,et al.SPAGNOLI G.Biological and environmental monitoring of hospital personnel exposed to antineoplastic agents:A review of analytical methods[J].J Chromatogr B Analyt Technol Biomed Life Sci,2003,789(2):169-209.
[16] SCHMAUS G,SCHIERL R,FUNCK S.Monitoring surface contamination by antineoplastic drugs using gas chromatography-mass spectrometry and voltammetry[J].Am J Health Syst Pharm,2002,59(10):956-961.
[17] TURCI R,SOTTANI C,RONCHI A,et al.Biological monitoring of hospital personnel occupationally exposed to antineoplastic agents[J].Toxicol Lett,2002,134(1-3):57-64.
[18] HEDMER M,TINNERBERG H,AXMON A,et al.Environmental and biological monitoring of antineoplastic drugs in four workplaces in a Swedish hospital[J].Int Arch Occup Environ Health,2008,81(7):899-911.
[19] CONNOR T H,DEBORD D G,PRETTY J R,et al.Evaluation of antineoplastic drug exposure of health care workers at three university-based US cancer centers[J].J Occup Environ Med,2010,52(10):1019-1027.
[20] SCHIERL R,BÖHLANDT A,Nowak D.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies[J]. Ann Occup Hyg,2009,53(7):703-711.
[21] MCDIARMID M A,OLIVER M S,ROTH T S,et al.Chromosome 5 and 7 abnormalities in oncology personnel handling anticancer drugs[J].J Occup Environ Med,2010,52(10):1028-1034.
[22] YOSHIDA J,KODA S,NISHIDA S,et al.Association between occupational exposure levels of antineoplastic drugs and work environment in five hospitals in Japan[J].J Oncol Pharm Pract,2011,17(1):29-38.
[23] CHU W C,HON C Y,DANYLUK Q,et al.Pilot assessment of the antineoplastic drug contamination levels in British columbian hospitals pre- and post-cleaning[J].J Oncol Pharm Pract,2012,18(1):46-51.
[24] KIFFMEYER T K,TUERK J,HAHN M,et al.Application and assessment of a regular environmental monitoring of the antineoplastic drug contamination level in pharmacies-the MEWIP project[J].Ann Occup Hyg,2013,57(4):444-455.
[25] HON CY,TESCHKE K,CHU W,et al.Antineoplastic drug contamination of surfaces throughout the hospital medication system in Canadian hospitals[J].J Occup Environ Hyg,2013,10(7):374-383.
[26] SUSPIRO A,PRISTA J.Biomarkers of occupational exposure do anticancer agents:A minireview[J].Toxicol Lett,2011,207(1):42-52.
[27] HON C Y,TESCHKE K,DEMERS P A,et al.Antineoplastic drug contamination on the hands of employees working throughout the hospital medication system[J].Ann Occup Hyg,2014,58(6):761-770.
[28] CONNOR T H,ZOCK M D,SNOW A H.Surface wipe sampling for antineoplastic(chemotherapy) and other hazardous drug residue in healthcare settings:Methodology and recommendations[J].J Occup Environ Hyg,2016,13(9):658-667.
[29] KIBBY T.A review of surface wipe sampling compared to biologic monitoring for occupational exposure to antineoplastic drugs[J].J Occup Environ Hyg,2017,14(3):159-174.
[30] POWER L A,COYNE J W.ASHP guidelines on handling hazardous drugs[J].Am J Health Syst Pharm,2018,75(24):1996-2031.
[31] CHAUCHAT L,TANGUAY C,CARON N J,et al.Surface contamination with ten antineoplastic drugs in 83 Canadian centers[J]. J Oncol Pharm Pract,2019,25(5):1089-1098.
[32] DUGHERI S,BONARI A,POMPILIO I,et al.Analytical strategies for assessing occupational exposure to antineoplastic drugs in healthcare workplaces[J].Med Pr,2018,69(6):589-604.
[33] SIMON N,ODOU P,DECAUDIN B,et al.Efficiency of degradation or desorption methods in antineoplastic drug decontamination:A critical review[J].J Oncol Pharm Pract,2019,25(4):929-946.
[34] ROUSSEL C,WITT K L,SHAW P B,et al.Meta-analysis of chromosomal aberrations as a biomarker of exposure in healthcare workers occupationally exposed to antineoplastic drugs[J].Mutat Res Rev Mutat Res,2019,781:207-217.
[35] GRAEVE C U,MCGOVERN P M,ALEXANDER B,et al.Occupational exposure to antineoplastic agents[J].Workplace Health Saf,2017,65(1):9-20.
[36] VERSCHEURE E,CRETA M,VANOIRBEEK J,et al.Environmental contamination and occupational exposure of algerian hospital workers[J].Front Public Health,2020,8:374.
[37] LABRÈCHE F,OUELLET C,ROBERGE B,et al.Occupational exposure to antineoplastic drugs:what about hospital sanitation personnel?[J].Int Arch Occup Environ Health,2021,94(8):1877-1888.
[38] DELAFOY C,ROUSSY C,HUDON A F,et al.Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 122 centers[J].J Oncol Pharm Pract,2023,29(2):338-347.
[39] ARNOLD S,KAUP H M.Assessing variability of antineoplastic drugs handling practices in clinical settings[J].J Occup Environ Hyg,2019,16(12):757-762.
[40] SOTTANI C,GRIGNANI E,CORNACCHIA M,et al.Occupational exposure assessment to antineoplastic drugs in nine italian hospital centers over a 5-year survey program[J]. Int J Environ Res Public Health,2022,19(14):8601.
[41] SCHIERL R,BÖHLANDT A,NOWAK D.Guidance values for surface monitoring of antineoplastic drugs in German pharmacies[J].Ann Occup Hyg,2009,53(7):703-711.
[42] SOTTANI C,PORRO B,COMELLI M,et al.An analysis to study trends in occupational exposure to antineoplastic drugs among health care workers[J].J Chromatogr B Analyt Technol Biomed Life Sci,2010,878(27):2593-2605.
[43] SOTTANI C,GRIGNANI E,ODDONE E,et al.Monitoring Surface contamination by antineoplastic drugs in italian hospitals:performance-based hygienic guidance values(HGVs) project[J].Ann Work Expo Health,2017,61(8):994-1002.
[44] QUARTUCCI C,ROONEY J P K,NOWAK D,et al.Evaluation of long-term data on surface contamination by antineoplastic drugs in pharmacies[J].Int Arch Occup Environ Health,2023,96(5):675-683.
[45] ROMBALDI F,CASSINI C,SALVADOR M,et al.Occupational risk assessment of genotoxicity and oxidative stress in workers handling anti-neoplastic drugs during a working week[J].Mutagenesis,2009, 24(2):143-148.
[46] SANTOS A N,OLIVEIRA R J,PESSATTO L R,et al.Biomonitoring of pharmacists and nurses at occupational risk from handling antineoplastic agents[J].Int J Pharm Pract,2020,28(5):506-511.
[47] GIANFREDI V,NUCCI D,FATIGONI C,et al.Extent of primary DNA damage measured by the comet assay in health professionals exposed to antineoplastic drugs:A systematic review and meta-analysis[J].Int J Environ Res Public Health,2020,17(2):523.
[48] URSINI C L,OMODEO SALÈ E,FRESEGNA A M,et al.Antineoplastic drug occupational exposure:A new integrated approach to evaluate exposure and early genotoxic and cytotoxic effects by no-invasive buccal micronucleus cytome assay biomarker[J].Toxicol Lett,2019, 316:20-26.
[49] HU J,ZHAO F,LIU L,et al.The meta-analysis of sister chromatid exchange as a biomarker in healthcare workers with occupational exposure to antineoplastic drugs[J].Medicine(Baltimore),2023,102(34):e34781.
[50] NESS S L R,MASCARENHAS M Á,ARBO M D,et al.Occupational exposure assessment in professionals who manipulate and administer antineoplastic drugs in a university hospital in Southern Brazil[J].J Oncol Pharm Pract,2021,27(5):1205-1213.